Nordic Life Science Days 2017 attracts interest worldwide as the region’s significance continues to grow
Malmö Sweden, September 7, 2017. Welcome to Nordic Life Science Days 2017 in Malmö, September 12-14, 2017. The 2½-day annual NLSDays has become an established arena for high quality meetings between investors, global companies and innovative Nordic companies. More than 1,200 delegates from all over the world are expected to attend.
“Like last year, when we had more than 2,200 scheduled meetings through the partnering system, we are confident that the conference will stimulate constructive contacts leading to collaborations with Nordic life science companies and new investments”, says Jonas Ekstrand, Director General at SwedenBIO, the Swedish life science industry organization. “The increasing number of scheduled meetings we have seen year by year confirms that Nordic Life Science Days meets an important need for Nordic start-ups, established international life science companies and global investors, alike.”
NLSD Super Sessions Tackle the Big Questions
As well as providing a 360 view of the thriving Nordic Life Science scene – companies, service providers, investors, research communities, and government and regulatory bodies – the 2½-day event also tackles the issues and opportunities facing the sector. Delegates will hear about game changing treatments for diabetic patients with closed loop systems and ultrafast acting insulin., together with innovative ways to fund lower-priority, yet high potential clinical trials. There will also be presentations on the little-recognised fact that many expert service providers, who are so important for the eco-system, drive frontline technology advancements. As a follow-up from last year’s program, the super session on Digital Health, sponsored by Abbvie and BMS, explores the collaboration opportunities between the health tech start-up arena and the Pharma industry. The other Super Sessions always spark lively debate and this year’s topics look sure to continue the tradition.
International experts on stage
One of the keynote speakers in the opening plenary session is Dr. Mikael Dolsten - President Worldwide Research and Development and EVP – Pfizer. Pfizer has for a long time had a considerable presence in Sweden with a large manufacturing facility for biologics and an active clinical development program. Dr. Dolsten is Swedish with an academic career from University of Lund, only 20 km from Malmö. The other keynote speakers are Mr. Mikael Odenberg - Chairman of the Board - Karolinska Institutet and Ms. Anita Krohn Traaseth - CEO - Innovasjon Norge.
Other international experts on stage include Dr. Søren Bregenholt - Novo Nordisk, Dr. Sven Kili – VP, Head of Cell & Gene Therapy Development, GSK, Dr. Gary Scler - Dana-Farber Cancer Institute, Dr. Anthony P. Sigrest – Director, Head of Patient Innovation- AbbVie and Lotta Ljungqvist – President & CEO, GE Nordic.
“The conference programme has come together well and we expect it will stimulate a lively debate on a number of challenges facing the life science industry and healthcare, not just the Nordics, but also globally”, says Jonas Ekstrand, Director General SwedenBIO.
The Nordics – a biotech stronghold in Europe
“NLSDays also takes place during a thriving period for the Nordic region. For example, last year’s pipeline report on drug development activities in Sweden presented a record-high 367 projects, of which 60% were preclinical. And these numbers only refer to Sweden - in a Nordic context, it is even more. The current trend for pharma companies to look for collaborations earlier and earlier in the value chain makes NLSDays increasingly relevant as a life science partnering event.”, continues Ekstrand.
There will also be a pre-conference fringe on September 12thwith two main events. First a coach tour to Lund, only 20 km outside Malmö to visit the recently inaugurated MAX IV facility and the under construction ESS. And then, don’t miss the Academic’s Catwalk and the Startups’ Challenge just before the Welcome Get Together.
NLSDays is a SwedenBIO event, produced by Bionordic. Nordic Life Science Days has grown rapidly since its launch in 2012 to become the largest Nordic partnering conference for the global life science industry. In 2016, 1,070 delegates from 36 countries attended the meeting. The 680 companies attending engaged in over 2,000 one-on-one meetings.
Among the investors and big pharma registered for the meeting include AbbVie, A. Menarini, Almi Invest, Amgen, AstraZeneca, Bayer, Bill & Melinda Gates Foundation, Boehringer Ingelheim, Bracknor Investment Group, Bristol-Myers Squibb, Cadila, CDC Investment Group, Daiichi Sankyo, Desitin ArzneimittelEA Pharma, Eli Lilly, Ferring Pharmaceuticals, Fouriertransform, Gilde Healthcare Partners, HealthCap, Huons, Hyundai Pharmaceuticals, Industrifonden, Johnson & Johnson, JT Pharma, Kyorin Pharmaceuticals, Medac, Mitsubishi Pharma, Monitus Research, MSD, Neomed, Novo Nordisk, Oberland Capital, Pathena VC, Pfizer, P.U.L.S., RBV Capital, Recordati, Reig Jofre, Roche, Saminvest, Sampoong Finechem, Sanofi, Sarsia Seed Fund, Servier, Seventure Partner, Sunstone, Taisho, Takeda, Thermo Fisher Scientific och UCB.
Venue: Malmömässan, Mässgatan 6, 215 32 Malmö, Sweden.
Time: September 12-14, 2017
Nordic Life Science Days on-line: http://www.nlsdays.com/
Nordic Life Science Days is a SwedenBIO event produced by Bionordic.
Complimentary registration is available for professional journalists and press representatives - Please contact the organizers.
General information: Olivier Duchamp, email@example.com., +33 (0) 608 804 515.
Regarding the conference program: firstname.lastname@example.org., +46 (0) 708 111 268.
Media-related: Ola Björkman, email@example.com., +46 (0) 70 245 74 97.
About SwedenBIO, http://swedenbio.se/information-in-english/
SwedenBIO, the trade association for the Swedish life science sector has more than 230 members operating across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves to the benefit the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to contribute to improving the conditions for the life science industry for the benefit of industry growth and business development. Sweden’s life science industry accounts for 20% of Sweden's net exports.
About Bionordic, http://www.bionordic.com
Bionordic is a full service global event management company that designs, plans and produces engaging conferences and corporate events for the life science industry. The organization supports a broad range of global clients including public and private agencies, non-governmental organizations, regional and multinational corporations.
Based on cutting edge technology solutions, Bionordic offer event services including strategic planning, venue selection and design through to cloud and database and community management tools.